ACTRIMS 2024 | Combination approaches in the treatment of NMOSD
Dalia Rotstein, MD, MPH, St. Michael’s Hospital and the University of Toronto, Toronto, ON, delves into the topic of combination therapy for treating neuromyelitis optica spectrum disorder (NMOSD). While the combination of prednisone with immunosuppressive agents like mycophenolate or azathioprine is widely accepted, other combination strategies are underutilized by clinicians. Dr Rotstein advocates for the consideration of combination approaches, particularly for patients resistant to monotherapy. This interview took place during the annual ACTRIMS Forum 2024.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dalia Rotstein reports the following disclosures: I have received research support from MS Canada, the National MS Society, CMSC, University of Toronto Division of Neurology, and Roche Canada. I have received consulting or speaker fees from Alexion, Amgen, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis.
